Brazil Drug Manufacturers - General news

08:10 12 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇧🇷 Brazil

Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?

Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, …

LILY34 mentioned

Sharemaestro market context Trend signal active 52 weeks +61.5%

03:53 12 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

3 Healthcare Stocks with Open Questions

3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over …

GILD34 mentioned

Sharemaestro market context Price below Trend Line 52 weeks +8.3%

23:15 11 Aug 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision …

ABBV34 main company

Sharemaestro market context Trend signal active 52 weeks +14.4%

22:11 11 Aug 2026

finance.yahoo.com Market update Main company 🇧🇷 Brazil

AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in …

ABBV34 main company

Sharemaestro market context Trend signal active 52 weeks +14.4%

21:05 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

MacroGenics, Inc. ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license …

GILD34 mentioned

Sharemaestro market context Price below Trend Line 52 weeks +8.3%

21:05 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇧🇷 Brazil

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half …

LILY34 mentioned

Sharemaestro market context Trend signal active 52 weeks +61.5%

20:34 11 Aug 2026

finance.yahoo.com Market update Main company 🇧🇷 Brazil

AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk

AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -2.6% · Next-week setup positive 58.2%

20:27 11 Aug 2026

finance.yahoo.com Deals and strategy Provider-linked mention 🇧🇷 Brazil

NovelMed Advances NM5072 for Multiple Ocular Disorders

NovelMed Therapeutics Inc Key Highlights Multi-indication precedent: Biogen's approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan. Primate proof of concept: A single intravitreal dose of NM5072 reduced CNV, hemorrhage, and retinal fibrosis in …

BIIB34 mentioned

Sharemaestro market context Trend signal active 52 weeks +38.9%

20:07 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's …

LILY34 main company N1VO34 mentioned

Sharemaestro market context Trend signal active 52 weeks +61.5%

19:14 11 Aug 2026

finance.yahoo.com Market update Main company 🇧🇷 Brazil

Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. …

MRCK34 main company

Sharemaestro market context Trend signal active 52 weeks +46.5%

18:20 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇧🇷 Brazil

2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now

Space Exploration Technologies (NASDAQ: SPCX) has been perhaps the most talked-about stock on Wall Street since it completed the largest IPO ever in mid-June. Opinions on the company's prospects are divided. Some see an innovative company that has already disrupted the space travel industry …

LILY34 mentioned

Sharemaestro market context Trend signal active 52 weeks +61.5%

17:54 11 Aug 2026

finance.yahoo.com Market update Main company 🇧🇷 Brazil

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% …

ABBV34 main company LILY34 mentioned JNJB34 mentioned

Sharemaestro market context Trend signal active 52 weeks +14.4%

17:45 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surged 120% year over …

PFIZ34 mentioned

Sharemaestro market context Price above Trend Line 52 weeks +4.1%

17:00 11 Aug 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Pfizer (PFE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 11:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Albert Bourla Chief Financial Officer - David Denton Incoming Interim Chief Financial Officer and Executive Vice President - Cecile Guegan Chief Scientific …

PFIZ34 main company

Sharemaestro market context Price above Trend Line 52 weeks +4.1%

16:26 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

N1VO34 mentioned

Sharemaestro market context Price above Trend Line 52 weeks -13.6%

16:12 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's …

LILY34 main company N1VO34 mentioned

Sharemaestro market context Trend signal active 52 weeks +61.5%

16:00 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

Tecan Group AG (TCHBF) (H1 2026) Earnings Call Highlights: Strategic Progress and Market ...

This article first appeared on GuruFocus. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tecan Group AG (TCHBF) delivered solid above-market growth in both segments, with group sales up …

N1VS34 mentioned

Sharemaestro market context Price above Trend Line 52 weeks +20.2%

15:11 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

Do Options Traders Know Something About AstraZeneca Stock We Don't?

Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is …

A1ZN34 mentioned

Sharemaestro market context Price below Trend Line 52 weeks -2.6% · Next-week setup positive 58.2%

15:04 11 Aug 2026

finance.yahoo.com Market update Main company 🇧🇷 Brazil

Hedge Funds are Bullish on AstraZeneca PLC (AZN)

AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug …

A1ZN34 main company

Sharemaestro market context Price below Trend Line 52 weeks -2.6% · Next-week setup positive 58.2%

14:48 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?

Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as …

MRCK34 mentioned A1ZN34 mentioned

Sharemaestro market context Trend signal active 52 weeks +46.5%

14:40 11 Aug 2026

seekingalpha.com Market update Provider-linked mention 🇧🇷 Brazil

These stocks have some of Wall Street’s lowest short interest

[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares …

LILY34 mentioned

Sharemaestro market context Trend signal active 52 weeks +61.5%

14:12 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum …

LILY34 mentioned JNJB34 mentioned

Sharemaestro market context Trend signal active 52 weeks +61.5%

14:00 11 Aug 2026

finance.yahoo.com Regulatory and legal Provider-linked mention 🇧🇷 Brazil

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"

A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA …

MRCK34 mentioned BIIB34 mentioned

Sharemaestro market context Trend signal active 52 weeks +46.5%

14:00 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration

Collaboration demonstrates how AI-powered Tissue Intelligence is transforming biomarker discovery, translational research, and precision oncology development. TEL AVIV, Israel, August 11, 2026--(BUSINESS WIRE)--Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced …

GILD34 mentioned

Sharemaestro market context Price below Trend Line 52 weeks +8.3%

13:44 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival …

LILY34 main company N1VO34 mentioned

Sharemaestro market context Trend signal active 52 weeks +61.5%

13:38 11 Aug 2026

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development …

N1VO34 main company

Sharemaestro market context Price above Trend Line 52 weeks -13.6%

13:31 11 Aug 2026

finance.yahoo.com Market update Main company 🇧🇷 Brazil

Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down …

PFIZ34 main company

Sharemaestro market context Price above Trend Line 52 weeks +4.1%

13:30 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business Officer Appointments deepen vaccine development expertise and enhance global commercial and strategic leadership WESTON, Fla., August 11, 2026--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage …

MRCK34 mentioned

Sharemaestro market context Trend signal active 52 weeks +46.5%

13:00 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices

Updated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growth Introduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customers IRVINE, Calif., Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today …

ABBV34 mentioned

Sharemaestro market context Trend signal active 52 weeks +14.4%

12:43 11 Aug 2026

nasdaq.com Analyst action Main company 🇧🇷 Brazil

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

N1VO34 main company

Sharemaestro market context Price above Trend Line 52 weeks -13.6%

12:05 11 Aug 2026

finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, …

ABBV34 main company

Sharemaestro market context Trend signal active 52 weeks +14.4%

12:03 11 Aug 2026

finance.yahoo.com Market update Main company 🇧🇷 Brazil

Veeva Vault CRM Selected by Eli Lilly and Company

PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of …

LILY34 main company

Sharemaestro market context Trend signal active 52 weeks +61.5%

08:30 11 Aug 2026

nasdaq.com Regulatory and legal Main company 🇧🇷 Brazil

Eli Lilly's Foundayo Wins UK Approval

(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory …

LILY34 main company

Sharemaestro market context Trend signal active 52 weeks +61.5%

06:43 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals

During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and …

A1ZN34 mentioned

Sharemaestro market context Price below Trend Line 52 weeks -2.6% · Next-week setup positive 58.2%

06:00 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed

Tecan Group AG Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed Financial highlights – first half …

N1VS34 mentioned

Sharemaestro market context Price above Trend Line 52 weeks +20.2%

02:03 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

OHB SE (WBO:OHB) (Q2 2026) Earnings Call Highlights: Record Backlog and Strategic Growth Amid ...

This article first appeared on GuruFocus. Total Operating Performance: EUR628 million in H1 2026, up from EUR470 million in H1 2024, representing double-digit growth. Adjusted EBITDA: EUR60 million, with a margin of 9.6%, reflecting a 30%+ increase year-on-year. Space Systems Segment Revenue: EUR472 million …

N1VS34 mentioned

Sharemaestro market context Price above Trend Line 52 weeks +20.2%